COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

At the recommended regimen, 73% of patients receiving a pasritamig and JNJ-9401 combination, two bispecific antibodies designed to work together to drive the body’s immune response against advanced prostate cancer, achieved reductions of at least 50% in prostate-specific antigen, according to the results of a first-in-human phase I study. 
I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login